Grewal Research Update: Highlights from NANETS 2026

By Udhayvir Singh Grewal, MD | Winship Cancer Institute of Emory University
Guest Contributor

Udhayvir Singh Grewal, MD

The 2026 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium highlighted several important advances in our understanding and treatment of neuroendocrine neoplasms (NENs). If there was one overarching theme at NANETS 2026, it was the growing momentum in extrapulmonary neuroendocrine carcinomas (epNECs). In his keynote address, Dr. Halfdan Sørbye reflected on decades of research that he and many others in our field have dedicated to understanding these aggressive malignancies. For years, we have recognized that platinum-based chemotherapy, while the mainstay of treatment, offers limited and often short-lived benefit. What struck me most about this year’s meeting was that we are finally moving beyond simply acknowledging the limitations of chemotherapy and actively doing something to move the needle forward. It is so refreshing to see that we finally are beginning to see promising therapeutic strategies emerge for a disease that has historically had very few options. In many ways, epNEC felt like the core theme of NANETS 2026. There is still a long way to go, but for the first time in a long time, I left the meeting with a genuine sense of optimism about where this field is headed. Other than encouraging progress in epNEC, this year’s NANETS symposium brought forth a wide array of research studies covering radioligand therapy, gene discovery and beyond. 

Early Phase Data for DLL3-Targeting Therapies

Two studies highlighted different approaches to targeting DLL3: antibody-drug conjugates (ADCs) and T-cell engagers. Both demonstrated encouraging early clinical activity in a disease where therapeutic advances have historically been limited.

Zocilurtatug Pelitecan: A DLL3-Targeted Antibody-Drug Conjugate

Dr. Amr Mohamed and colleagues presented results from a phase 1b study evaluating zocilurtatug pelitecan (Zoci, formerly ZL-1310), a novel DLL3-targeted ADC, in patients with advanced epNECs who had experienced disease progression following platinum-based chemotherapy. Among 34 response-evaluable patients, the confirmed objective response rate (ORR) was 38.2%, with a disease control rate of 55.9%. Responses were observed across gastroenteropancreatic and non-gastroenteropancreatic NECs. Interestingly, patients with higher DLL3 expression demonstrated numerically greater response rates (50.0% versus 26.7%), although no definitive association between DLL3 expression and response was established. Among 46 treated patients, grade 3 or higher treatment-emergent adverse events occurred in 30.4%. While progression-free survival and duration of response data remain immature, these findings are encouraging in the post-platinum setting, where effective treatment options remain limited. The study has expanded into phase 2 to further evaluate efficacy and durability of response.

DAREON-7: Bringing Obrixtamig Into the First-Line Setting

Dr. Aman Chauhan and colleagues presented updated results from the phase 1b DAREON-7 study evaluating obrixtamig (BI 764532), a DLL3-directed CD3 T-cell engager, in combination with platinum-etoposide chemotherapy as first-line treatment for advanced epNECs. The analysis included 44 patients, including 40 with epNEC. Investigators evaluated outcomes according to DLL3 expression, comparing tumors with high expression (≥50% of tumor cells with moderate-to-strong staining) against those with lower expression. Encouraging clinical activity was observed across both DLL3-expression subgroups, with a trend toward improved outcomes in patients with higher DLL3 expression. Cytokine release syndrome (CRS) was predominantly low grade, occurring at grade 1 in 59% and grade 2 in 14% of patients, with no grade 3 or higher CRS or grade 2 or higher immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Notably, investigators described a patient with metastatic vaginal NEC who achieved a complete response following combination treatment and subsequent obrixtamig maintenance. These findings support the ongoing phase 3 DAREON-NEC-1 trial, which is evaluating whether adding obrixtamig to platinum-etoposide improves outcomes for patients with DLL3-expressing advanced epNECs.

My take: It is exciting to see so much progress in this space. It is important for us to appreciate that T-cell engagers like Obrixtamig have particularly better outcomes in DLL3-high disease; although some of that clustering of responses in DLL3-high disease seems to be offset by chemotherapy combination- generating encouraging efficacy across DLL3-expression subgroups. On the other hand, efficacy with Zoci does not seem to correlate with DLL3 expression. I hope to see sequential use of these agents in the future, recognizing that DLL3 expression may drop following treatment with T-cell engagers, which would still retain ADCs like Zoci as a viable therapeutic option. 

Radioligand Therapy: What’s New and Revisiting The Old

Radioligand therapy (RLT) continues to transform the treatment landscape for patients with advanced neuroendocrine tumors (NETs). At NANETS 2026, several studies highlighted important advances in this field, ranging from promising early results with alpha-emitting radiopharmaceuticals to a better understanding of resistance mechanisms and long-term hematologic toxicity.

Early Results With ²¹²Pb-VMT-α-NET

Dr. Thorvardur Halfdanarson and colleagues presented results from an ongoing phase 1/2a study evaluating ²¹²Pb-VMT-α-NET, an investigational alpha-emitting radioligand therapy targeting somatostatin receptor subtype 2 (SSTR2), in patients with advanced, well-differentiated NETs who had progressed following prior systemic therapy. Unlike the beta-emitting ¹⁷⁷Lu-DOTATATE, ²¹²Pb-VMT-α-NET delivers high-energy alpha radiation over a shorter tissue range, potentially allowing more localized tumor cell killing. As of April 2026, 68 patients had received at least one dose across three dose-escalation cohorts. Among 23 patients in the first half of Cohort 2 (185 MBq) with efficacy data, the objective response rate was 43.5% (10/23), including nine confirmed partial responses. Both patients treated at the lowest dose level maintained stable disease after two years of follow-up. Importantly, no dose-limiting toxicities, grade 4–5 treatment-emergent adverse events, serious renal events, or clinically meaningful treatment-related myelosuppression were reported. Median follow-up across all treated patients was 10.6 months.

My take: Although these findings are preliminary and based on a relatively small efficacy-evaluable population, they suggest encouraging antitumor activity with a favorable early safety profile. I, as others in the field, remain very excited about this space. With the recent announcement regarding positive results of ACTION-1, it will be interesting to see where alpha PRRT fits in the treatment landscape of NETs. Outside of long-term efficacy data, safety remains an important concern. I sincerely hope we can focus on developing biomarkers to personalize decisions in clinic for our patients. 

Tumor Microenvironment and Resistance to PRRT

Dr. Abbu and colleagues from the University of Chicago presented an important translational study exploring how changes in the tumor microenvironment may contribute to resistance to ¹⁷⁷Lu-DOTATATE. The investigators analyzed 58 tumor lesions from 13 patients with well-differentiated pancreatic or small bowel NETs, integrating multiplex immunofluorescence, genomic profiling, and RNA sequencing. Interestingly, tumors progressing after PRRT demonstrated significantly greater CD8-positive T cell infiltration compared with non-progressing lesions. However, these tumors also exhibited increased PD-L1 expression on macrophages and other tumor compartments, suggesting that greater immune infiltration may not necessarily translate into effective antitumor immunity. Progressing tumors also demonstrated reduced SSTR2 expression, potentially limiting radioligand delivery. Additional analyses identified distinct resistance-associated pathways in pancreatic and small intestinal NETs, including PI3K-Akt signaling and epithelial-mesenchymal transition, respectively. 

My take: These findings suggest that resistance to PRRT may involve both reduced radioligand uptake and an immunosuppressive tumor microenvironment. It will be interesting to see how translational data from ongoing efforts to study combination strategies with PRRT unfold. Modulating the tumor immune microenvironment might represent a unique opportunity to maximize the therapeutic efficacy of PRRT. 

Understanding the Risk of Therapy-Related Myeloid Neoplasms

Drs. Charles W. Shi, Deevyashali Parekh (Emory University and Montefiore Medical Center, respectively) and colleagues, presented a multicenter real-world study examining the risk of therapy-related myeloid neoplasms (t-MNs) following ¹⁷⁷Lu-DOTATATE treatment. Using the TriNetX research network, investigators identified 1,811 patients with NETs who received ¹⁷⁷Lu-DOTATATE. With a median follow-up of 20.5 months, 52 of 1,804 evaluable patients (2.88%) developed a subsequent myeloid neoplasm, including myelodysplastic syndrome (MDS) in 2.05% and acute myeloid leukemia (AML) in 0.83%. On multivariable analysis, older age and preexisting chronic kidney disease were independently associated with an increased risk of t-MNs. Interestingly, prior temozolomide exposure and repeat PRRT were not significantly associated with increased risk in this cohort. 

My take: Although t-MNs remain uncommon, they represent a serious potential long-term complication of PRRT. These findings highlight the importance of individualized risk assessment, patient counseling and continued hematologic surveillance, particularly as PRRT moves into earlier treatment settings. However, these findings should be interpreted cautiously given the observational study design and relatively limited follow-up. I am hopeful that clonal hematopoiesis of indeterminate potential (CHIP) may represent an important biomarker to inform individualized risk assessment. 

MTAP Loss in Neuroendocrine Tumors?

Dr. Danping Niu and colleagues from MD Anderson Cancer Center presented an intriguing study identifying epigenetic loss of methylthioadenosine phosphorylase (MTAP) as a potentially targetable vulnerability in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Unlike many other cancers, where MTAP loss typically results from genomic deletion, investigators found that MTAP expression in well-differentiated NETs can be suppressed through epigenetic mechanisms despite preservation of the underlying gene. Among 37 tumor specimens analyzed, MTAP protein loss was observed in 76.5% (13/17) of small intestinal NETs and 25% (5/20) of pancreatic NETs. Importantly, genomic analysis demonstrated retention of the MTAP locus in small intestinal NETs with loss of protein expression, suggesting an epigenetic rather than genetic mechanism. Using NET cell lines and patient-derived organoid models, investigators demonstrated that MTAP loss resulted in accumulation of methylthioadenosine (MTA) and reduced PRMT5 activity, creating a potential therapeutic vulnerability. Experimental MTAP knockout increased sensitivity to inhibitors of PRMT5 and MAT2A, two enzymes involved in cellular methylation pathways. 

My take: I find these data to be very intriguing. These findings are particularly interesting because MTAP loss has traditionally been investigated as a therapeutic biomarker in cancers with genomic MTAP deletions. This study suggests that epigenetically silenced MTAP may create a similar therapeutic opportunity, potentially expanding the population of patients who could benefit from PRMT5- or MAT2A-targeted therapies. I hope there will be an opportunity to engage industry to launch a phase II study to investigate PRMT5 or MAT2A inhibitors in progressive NETs.

Even though we all just got back from Vegas, I can barely wait for what NANETS 2027 will bring. See you all in Scottsdale AZ!

__________________________________________________________________________________________________

Udhayvir Singh Grewal, MD, is a gastrointestinal and neuroendocrine medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Hematology and Medical Oncology at Emory University School of Medicine. 

The views and opinions expressed in this article are those of the author and do not necessarily reflect those of the Neuroendocrine Tumor Research Foundation (NETRF).

More from NANETS 2026: Read NETRF Chief Scientific Officer Anna Greene, PhD’s, reflections on the meeting, including emerging research directions, the importance of collaboration, and how NETRF is working to advance scientific discoveries that matter to patients.